Dr Said Khelwatty


I began my higher education at Kingston University in 2005 with an undergraduate degree in Biomedical Sciences. Upon graduating in 2008, I undertook a MSc degree in Biomedical Sciences, specialising in Haematology. Subsequently, I started my PhD in Cancer biology and therapeutics in (2009-2012) at Kingston University. 

In 2013, I began my tenure as a Postdoctoral Fellow and have worked on several research projects in translational cancer research field, which focuses on finding predictive biomarkers for targeted therapy of colorectal cancer patients and was externally funded by BRIGHT charity, and as a result was also able to gain the fellowship of the Institute of Biomedical Sciences. 

I was appointed to a lectureship within the School of Life Science, Pharmacy and Chemistry at Kingston University in 2018. I currently teach on a range of bioscience programmes and very much research active with a focus on colorectal cancer diagnosis and therapy. 

Academic responsibilities

Senior Lecturer in Clinical Immunology


  • Fellow of Advance Higher Education (FHEA), 2020
  • Fellow Institute of Biomedical Science (FIBMS), 2015
  • PhD Cancer Biology and Therapeutics, 2012
  • MSc Biomedical Sciences, 2009
  • BSc (Hons) Biomedical Sciences, 2008

Teaching and learning

Module Leader 

LS7001 - Research Techniques & Scientific Communication

LS7010 - MSc Research Project Module

Undergraduate courses taught

Postgraduate courses taught


I have an extensive research background with particular expertise in translational cancer research. I draw strong technical and analytical expertise in biological and clinical significance of growth factor receptor family with tyrosine kinase activity and cancer stem cells in human malignancies, in particular colorectal cancer.

Currently my research interests are in the following areas:

1. Biological and clinical significance and targeting of growth factor receptors with tyrosine kinase activities in human cancers.

2. Predictive biomarkers for response to therapy in colorectal cancer.

3. Development of monoclonal antibody (mAb) products for use in colorectal cancer diagnosis and therapy

Research Student Supervision

Ms Noor Khalaf - Brain Cancer

Ms Narmin Nahi - Stomach Cancer

Areas of specialism

  • Cell Culture
  • Histopathology
  • Molecular Diagnostics
  • Drug Resistance Development
  • Monoclonal Antibodies

Scholarly affiliations

  • British Association for Cancer Research
  • American Association for Cancer Research


Number of items: 10.


Khan, Tanzeel, Seddon, Alan M., Dalgleish, Angus G., Khelwatty, Said, Ioannou, Nikolaos, Mudan, Satvinder and Modjtahedi, Helmout (2020) Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations : implications for future clinical trials in pancreatic cancer. Oncology Reports, 44(6), pp. 2581-2594. ISSN (print) 1021-335X

Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan M. and Modjtahedi, Helmout (2019) Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer. Oncotarget, 10(18), pp. 1704-1715. ISSN (online) 1949-2553

Puvanenthiran, S., Essapen, S., Haagsma, B., Bagwan, I., Green, M., Khelwatty, S. A., Seddon, A. M. and Modjtahedi, H. (2018) Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer. Oncotarget, 9, pp. 19662-19674. ISSN (online) 1949-2553

Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout (2016) The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget, 8(5), pp. 7666-7677. ISSN (online) 1949-2553

Khelwatty, Said A., Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout (2015) Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. British Journal of Cancer, 113(7), pp. 1010-1019. ISSN (print) 0007-0920

Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout (2014) Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PloS one, 9(3), e91139. ISSN (print) 1932-6203

Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan Michael and Modjtahedi, Helmout (2013) Prognostic significance and targeting of HER family in colorectal cancer. Frontiers in Bioscience, 18(2), pp. 394-421. ISSN (print) 1093-9946

Modjtahedi, H., Khelwatty, S.A., Kirk, R.S., Seddon, A.M., Essapen, S., Del Vecchio, C.A., Wong, A.J. and Eccles, S. (2012) Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. British Journal of Cancer, 106, pp. 883-888. ISSN (print) 0007-0920

Conference or Workshop Item

Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout (2013) Acquired resistance to anti-EGFR mAb ICR62 or afatinib is accompanied by upregulation of the EGFR in colorectal cancer. In: 104th Annual Meeting of the American Association for Cancer Research; 6-10 Apr 2013, Washington, U.S.A..


Khelwatty, Said Abdullah (2012) The biological and clinical significance of HER family members and cancer stem cells in colorectal cancer and response to therapeutic interventions. (PhD thesis), Kingston University, uk.bl.ethos.579135.

This list was generated on Fri Nov 27 06:30:19 2020 GMT.